Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
COVID vaccine news dominates our last monthly round-up of articles from Springer Nature research journals, magazines and supplements of the year. The articles explore how the many vaccines in development are affecting the pharmaceutical sector and what challenges lie ahead for their rollout.
Montreal-based Inversago Pharma is developing a portfolio of peripherally-acting cannabinoid receptor-1 (CB1) inverse agonists, including its lead candidate INV-101, in development for the treatment of the rare genetic disorder Prader-Willi syndrome (PWS), NASH and other conditions.
After a decade of uncertainty, a trio of clinical trial successes in 2020 is spurring enthusiasm about the potential for effectively treating disease via manipulation of the gut microbiome.
Pfizer’s Centers for Therapeutic Innovation and other partnership initiatives champion emerging science and help stakeholders realize the potential of their innovations.
The maturation of oligonucleotide and gene therapies, and the birth of the gene editing revolution, are spurring innovation in the cardiovascular and metabolic disease space.
Anthos is developing a pioneering phase 2 monoclonal antibody, abelacimab, as an effective anticoagulant that aims to provide treatment by inhibiting Factor XI to avoid severe bleeding.
The CanVirex platform deploys the oncolytic properties of recombinant measles vectors for innovative cancer treatments. In addition it has now provided a novel COVID-19 vaccine candidate that is approaching clinical trials.
RevoluGen has designed Fire Monkey, a fast, easy-to-use spin column that extracts optimal DNA for long-read sequencing and is already being used in a number of applications.
Genome & Company is developing a microbiome-based add-on therapy for programmed cell death 1/programmed cell death 1 ligand 1 inhibitors. It is also developing novel targeted immune checkpoint inhibitors and believes these two approaches could be combined for personalized therapy.
Actimed Therapeutics is developing anabolic/catabolic transforming agents: a new class of agents to treat cachexia, an often fatal condition associated with many chronic diseases including cancer.
Axial Therapeutics focuses on the gut–brain axis to develop therapeutics to mitigate central nervous system disorders and conditions. The company has built a pipeline of novel small molecules with lead programs in autism spectrum disorder and Parkinson’s disease.
Maximizing the potential of the resident gut microbiome, Kaleido Biosciences is developing novel glycans with the ability to change the metabolic output of the microbiome and have a clinically significant impact across a broad range of diseases.
Precision NanoSystems empowers researchers to develop genetic medicines through its NanoAssmblr technology, helping companies solve drug delivery challenges in both cancer and infectious diseases.